Is the specific chemical derivatization of our iMBP-001 lead molecule to adjust specific biological, kinetic and clearance characteristics. These alterations are essential to appropriately address different diseases. In doing so, new molecular entities with independent intellectual property lines are created.
iMetabolic Biopharma is advancing its early stage pipeline based upon the application of the iPlatform. These therapeutic candidates are poised to address the unique biology, current unmet needs and complex medical challenges of patients in several pathologically related indications.
Due to superior operational efficiency in tandem with iPlatform, iMBP has been able to expedite the evolution of its pipeline. With accelerating program development, it is the goal of the company to continue in this pipeline expansion.